Physician profile
Robert B Mckeeman
NPI 1730164484
$1,824.82
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $452.36 | 2019-2020 | |
| Pfizer INC. | $248.05 | 2019 | |
| Glaxosmithkline, LLC. | $239.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.39 | 2019 | |
| Allergan, INC. | $112.64 | 2019 | |
| Sunovion Pharmaceuticals INC. | $111.20 | 2019 | |
| Novo Nordisk INC | $109.42 | 2019 | |
| Abbvie INC. | $96.64 | 2019 | |
| Amgen INC. | $65.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.08 | 2019-2020 | |
| Acorda Therapeutics, INC | $15.31 | 2019 | |
| Merck Sharp & Dohme LLC | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mckeeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.